GLPwatch

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

NCT04938388 · Terminated

Last updated 2026-05-28

This clinical trial is testing whether oral semaglutide, compared to a placebo, helps Latino adults with type 2 diabetes better manage their blood sugar levels when combined with lifestyle changes.

Status Terminated Stopped early and will not restart.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, triple-blind basic-science study
Participants 12 people
Who can join Ages 18+ · all sexes
Timeline Started 2022-01 · est. completion 2023-02
Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04938388 ↗

Description as written by the study sponsor.

Researchers at Sansum Diabetes Research Institute want to learn more about how taking a new approved drug called oral Semaglutide, while eating fresh vegetables, impacts health in Hispanic/Latino adults with type 2 diabetes. This study drug is approved by the United States Food and Drug Administration and may be available by prescription for type 2 diabetes. To do this, 100 Hispanic/Latino adults who have type 2 diabetes will be split into two groups. Over one year, one group will take Semaglutide pills and the other group will take a placebo (a dummy pill that looks just like the real Semaglutide pill but does not contain the active drug). Neither the participants nor the study investigator nor the study doctor will know who is taking the real pill and who is taking the placebo. In case of an emergency, however, the study investigator and doctor can get this information. All participants will receive pills and vegetables every two weeks, have their health assessed by study staff, and meet with the study doctor six times over the course of the study. Participant weight, height, waist circumference, blood pressure, and blood glucose levels will be measured. Participants will also wear monitors to measure blood glucose, physical activity and sleep. Study staff will also ask questions about participant health, medications, mood, sleep, pain, exercise, diet, acculturation, household, language, and trust in doctors.

Treatments tested

Main thing measuredHbA1c < 7.0%
SponsorSansum Diabetes Research Institute
Conditions studiedDiabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04938388 ↗